Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zovaglutide PK and Safety in Renal Insufficiency
NCT07443059Phase 1Active, not recruiting
- Sponsor
- QL Biopharm
- Start
- Apr 2026
- Primary completion
- Dec 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of zovaglutide in obesity (4 arms), sponsored by QL Biopharm. Primary endpoints: Area Under the Concentration Versus Time Curve From Time Zero to Tlast at Day 50, Maximum Concentration at Day 50 and 5 more. Started Apr 2026; status: active, not recruiting.
02
Drugs
zovaglutide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07443059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07443059.